Artificial Intelligence
The global fractional flow reserve market is expected to grow at a CAGR of 12% during 2022-2027
New York, June 22, 2022 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Fractional Flow Reserve Market – Global Outlook & Forecast 2022-2027” – https://www.reportlinker.com/p06288136/?utm_source=GNW
The benefits of FFR are high; however, its usage is limited in the market. The FFR is commonly used to decide the need for revascularization. The usage of non-invasive fractional flow reserve systems is increasing due to innovative methods in healthcare systems. As a part of the standard procedure to diagnose coronary artery disease (CAD), multiple non-invasive tests are performed on the patients complaining of stable chest pain and low or intermediate probability of CAD. Chest pain remains the second most common reason for adult emergency visits in the United States.
The increasing target population globally drives the demand for FFR systems.
The increasing target population will be a major driving factor for the usage of FFR in the market. Cardiovascular diseases cause one-third of deaths worldwide. Ischemic heart disease (IHD) is one of the prevalent conditions. The IHD incidence is expected to increase due to an increase in obesity, metabolic syndrome, diabetic conditions, and the aged population. In the past two decades, there has been a significant increase in the aging population. According to the United Nations, one in every eleven people will be over 65 years old by 2050, up from one in every eleven in 2019. In addition, reduced physical activity, rapid urbanization, and globalization activities in LMICs have led to an increase in cardiovascular diseases, including IHD. In countries like the United States, the cost of IHD is approaching 1%-1.5% of the gross domestic product (GDP); in the case of LMICs, it accounts for 10% of total per capita healthcare expenditure. This increasing target population globally will drive the global fractional flow reserve market growth.
Technological Advancements Driving the Faster adoption of FFR.
The fractional flow reserve market is experiencing high technological advancements with non-invasive FFR methods. This trend is augmenting the demand and adoption of next-generation FFR products among healthcare providers and end-users. The vendors such as Boston Scientific, Philips, and ACIST Medical Systems have launched the next-generation products in the market. Artificial intelligence (AI) and machine learning also played an essential role in giving real patient experiences with FFR products. In comparison with conventional methods, AI technology has helped the end-users analyze a large volume of cases in a shorter duration and provide equal quality treatment to all the patients irrespective of the number of patients diagnosed at the same time. The end-users adopt image-based techniques such as FFR-CT and FFRangio more frequently due to the non-invasive assessment of coronary lesions.
SEGMENT ANALYSIS
Technology
The invasive fractional flow reserve systems are widely accepted as a standard technique for assessing the lesion-specific ischemic in patients with 50% to 90% of stenosis. The advancement in the invasive segment is limited. For instance, in 2020, Philips launched the first solid core pressure guidewire for the coronary interventional procedure.
The number of people admitted to the CATH labs is decreasing in developed countries due to the change in better diagnostics of coronary artery disease. The non-invasive method is revolutionizing the cardiac diagnostic segment. The FFR-CT has helped reduce the number of patients referred for unnecessary catheterization. There are many scenarios in which the patient is recommended for stents and other procedures without proper quality data, where invasive FFR is ineffective in diagnosing the patient’s condition. The FFR-CT (non-invasive) has proven to be better than the FFR invasive, seen as a gatekeeper for CATH Labs in the market.
Application
The technological advancements in the market have made the clinicians diagnose the patient with multivessel diseases, which is a complex scenario for the invasive methods in the market. Non-invasive methods provide the 3D structure of the heart with the FFR value and indicate the possible stenosis locations. This is a major revolutionary product to treat patients with multivessel diseases. There is a constant increase in people admitted to hospitals suffering from multivessel diseases, especially in developing and developed countries.
End-User
Hospitals & Specialty Cardiac Centers: Hospitals are the first point of contact for any patients, especially during the emergency conditions like chest pain. This increases the number of people preferring the hospitals to undergo treatments, and Hospitals do invest in the latest technologies to attract better customers in the region. Most elective surgeries and complex cardiac surgeries are performed in specialty cardiac centers.
Office-Based Labs: It is one of the new evolutions in the laboratory spaces. The movement of people and doctors away from the hospitals to get better attention, and safer and quickest treatments are driving the demand for the new labs like office-based labs in the market.
Diagnostic Imaging Centers predominantly invest in advanced products to attract customers; they partner with a large number of clinics and hospitals providing the services indirectly. They are expected to grow at a faster CAGR during the forecast period.
Segmentation by Technology?
• Invasive
• Non-Invasive
Segmentation by Applications
• Single-Vessel
• Multi-Vessel
Segmentation by End-Users?
• Hospitals & Specialty Cardiac Centers
• Office-Based Labs
• Diagnostic Imaging Centers
• Others
Geography
Many developed countries like the US are shifting from the volume-based to value-based approach in the healthcare systems. This is making the developed countries prefer advanced products like FFR-CT. Some European countries prefer using value-based products to enhance their quality of treatments, which is not the case with developing countries like India, China, Brazil, Mexico, and Turkey. Still, the preference is majorly for volume-based treatments, which are economical and provide results to treat the patients.
North America: The United States dominated the global fractional flow reserve market globally. The faster adoption of value-based products in the healthcare system, better awareness among the clinicians, and increasing adoption of FFR-CT has made the US a major fractional flow reserve market shareholder.
Europe: Europe healthcare is a mixture of both values-based and volume-based healthcare providers. The adoption is faster among the value-based treatment providers. The adoption of advanced technologies is low in some of the developing economies in Europe. The increasing number of CATH Labs and office-based labs are mainly driving the usage of advanced products and boosting the non-invasive fractional flow reserve market.
APAC: The adoption of advanced products like FFR is limited in the region. There is a constant increase in the number of cardiovascular disease patients in the region, and the number of people undergoing diagnostics is increasing. The demand for invasive methods is still high in the APAC region compared to non-invasive techniques. Due to its increased potential in the market, it is expected to grow at its highest during the forecast period.
Latin America: Latin American countries are also seen as famous destinations for various medical treatments. The adoption of advanced technologies is high in urban hospitals to attract tourists. Due to lack of reimbursement, the usage by local patients is limited, and they prefer undergoing more economic tests in the market. In addition, the lack of skilled lab technicians also limits the people to use conventional methods in the market.
Middle East & Africa: The middle east& Africa region is growing at a lower CAGR than other countries. As per the recently available data, there are more than 1.1 billion people in that region, but only 20 countries have CATH labs. The potential for FFR-based products is high in the market due to the increased target population. The fractional flow reserve market demand will increase with more economical products.
Segmentation by Geography?
• North America
o US
o Canada
• Europe
o Germany
o France
o UK
o Italy
o Spain
• APAC
o China
o India
o South Korea
o Australia
• Latin America
o Brazil
o Mexico
o Argentina
• Middle East & Africa
o Turkey
o South Africa
o Saudi Arabia
VENDOR ANALYSIS
Abbott, ACIST Medical Systems, Boston Scientific, CathWorks, General Electric Company, Koninklijke Philips, Opsens, and Siemens Healthineers are key players in the global fractional flow reserve market.
Vendors like HeartFlow are applying advanced methodologies to launch better products. Their technology uses the competitional fluid dynamics model, proper segmentation of coronaries, helping to find the value through the place of interest, and produces an interactive image with the FFR values for the doctors to make accurate decisions. In addition, one of the major benefits of this FFR-CT is that it avoids the invasive angiogram and provides better results comparatively. In addition, they are also using AI technology for better enhancement of the results and accuracy in diagnostics.
Key Vendors?
• Abbott?
• ACIST Medical Systems
• Boston Scientific
• CathWorks
• General Electric Company
• Koninklijke Philips
• Opsens
• Siemens Healthineers
KEY QUESTIONS ANSWERED
1. What is the estimated value of the global fractional flow market?
2. What is the growth rate of the global fractional flow market?
3. Which region has the highest growth rate in the Fractional Flow Reserve Market?
4. Which region has the largest Fractional Flow Reserve Market share globally?
5. Who are the key players in the FFR market?
Read the full report: https://www.reportlinker.com/p06288136/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.
__________________________
Artificial Intelligence
Enghouse Video Partners With SONIFI Health To Deliver Advanced Telehealth Solutions In Hospital Rooms
MARKHAM, ON, April 25, 2024 /PRNewswire/ — Enghouse Video, a global leader in cutting-edge video technology solutions, today announced its partnership with SONIFI Health, enhancing virtual care in hospital settings.
SONIFI Health is a leading U.S. healthcare technology company based in Sioux Falls, South Dakota. The new partnership leverages and integrates Enghouse Video room systems technology to support SONIFI Health’s commitment to expanding telehealth applications and system optimizations in hospital settings.
Enghouse’s VidyoRooms solution, a sophisticated video conferencing technology that combines both software and hardware solutions, has been fully integrated into SONIFI Health’s interactive TV systems. This integration provides up to 4K high-quality video conferencing, multi-party sessions and robust security features that ensure full compliance with healthcare regulations.
Enghouse Video offers an immersive telehealth platform to support collaborative interdisciplinary care, improved patient outcomes and cost savings. The platform is flexible and simple, delivering the reliability, interoperability, and scalability needed for today’s healthcare environment. A key strength of the partnership is its offering of back-end integrations like patient portals, medical devices, EMR, tele-sitting, remote patient observation and consultation.
“Hospitals can choose the telehealth partner that’s right for them, and we incorporate that solution with interactive TV,” said Brian Nido, SONIFI Health’s Vice President of Customer Success. “Using the hardware and systems they already have in patient rooms helps hospitals reduce costs and maximize the value of their existing investments, while benefiting both clinicians and patients.”
SONIFI Health and Enghouse Video continue to collaborate closely to further refine and enhance the telehealth solutions provided to healthcare facilities. This partnership reflects a shared commitment to leveraging technology to create smarter hospital rooms and improve patient care across the healthcare spectrum.
About Enghouse VideoEnghouse Video, part of the Enghouse Interactive division, is a subsidiary of Enghouse Systems Limited, a vertically focused software and services company traded on the Toronto Stock Exchange (TSX: ENGH). Through highly secure, scalable and flexible Cloud-based or On Prem services, we deliver one of the world’s highest quality and most innovative video platform to video-enable any application or idea. From advanced video conferencing and collaboration tools to state-of-art enterprise video management, Enghouse Video is a unique player in multiple markets, including telehealth. Learn more at www.enghousevideo.com, read our blog, or follow us on Twitter at @EnghouseVideo, on LinkedIn, and on Facebook.
About SONIFI HealthSONIFI Health provides market-leading interactive patient engagement technology proven to improve patient outcomes and staff productivity. The EHR-integrated platform is designed to enhance patient and family experiences while increasing staff satisfaction and organizations’ operational efficiencies. As part of SONIFI Solutions, Inc., the company annually supports more than 300 million end user experiences. Learn more at sonifihealth.com.
Enghouse Video Contact: Sylvain Awad, Director, Demand Generation, Enghouse Video, part of Enghouse Interactive Division, [email protected]
View original content:https://www.prnewswire.co.uk/news-releases/enghouse-video-partners-with-sonifi-health-to-deliver-advanced-telehealth-solutions-in-hospital-rooms-302126882.html
Artificial Intelligence
Global Insurance Provider Selects 3CLogic to Streamline AI and Contact Center Capabilities with ServiceNow
Multinational Insurance Broker to deploy 3CLogic’s solution with ServiceNow’s Financial Service Operations (FSO) platform to streamline customer experiences.
ROCKVILLE, Md., April 25, 2024 /PRNewswire/ — 3CLogic, the leading Conversational AI and Contact Center solution for ServiceNow®, today announced its selection by a global insurance provider to replace its existing contact center infrastructure as part of a larger CX transformation effort. The strategic decision is designed to complement the organization’s use of ServiviceNow’s Financial Services Operations (FSO) offering leveraged across a number of its existing product lines including Customer Warranty Claims, Roadside Assistance, and Home Warranties.
Serving millions of customers worldwide with innovative insurance and protective products, the organization required a solution that would enhance its recent investment in the ServiceNow platform as it works to transform its end-to-end customer service operations. The deployment will incorporate several of 3CLogic’s AI-powered capabilities purpose-built for ServiceNow, including Conversational AI, Speech Analytics, and AI Performance & Coaching, along with integrated call transcriptions, convenient 2-way SMS, and ServiceNow-centralized contact center reporting.
“We continue to see enterprises eager to complement their existing investment in digital platforms, such as ServiceNow, with contact center features purpose-built to extend the workflows and features they already have and use,” explains Matt Durkin, VP of Global Sales at 3CLogic. “It’s no secret that organizations are already juggling too many systems, often with overlapping capabilities, which impacts ROI and operational efficiency. We’re proud to offer an alternative approach that helps simplify the technology stack while optimizing the overall operational costs and outcomes.”
Recently named to Constellation Research’s 2024 Shortlist for Digital Customer Service and Support, 3CLogic has seen global adoption of its solution by leading enterprises in healthcare, manufacturing, travel, retail, higher education, finance, non-profits, and Managed Service Providers across five continents. As a ServiceNow-certified Technology and Build partner with offerings available for ServiceNow’s IT Service Management, Customer Workflows, HR Service Delivery, and Source-to-Pay solutions, the company will be unveiling its latest set of capabilities at ServiceNow’s annual Knowledge 2024 event this May in Las Vegas.
For more information, please contact [email protected].
About 3CLogic3CLogic transforms customer and employee experiences with its leading Cloud Contact Center and AI solutions purpose-built to enhance today’s leading CRM and Customer Service Management platforms. Globally available and leveraged by the world’s leading brands, its offerings empower enterprise organizations with innovative features such as intelligent self-service, generative and Conversational AI, agent automation & coaching, and AI-powered sentiment analytics – all designed to lower operational costs, maximize ROI, and optimize each interaction across IT Service Desks, Customer Support, Sales or HR Services teams. For more information, please visit www.3clogic.com.
Logo – https://mma.prnewswire.com/media/2318845/3CLogic_logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/global-insurance-provider-selects-3clogic-to-streamline-ai-and-contact-center-capabilities-with-servicenow-302127739.html
Leading Breast AI Company, creator of industry-leading Transpara®, promotes from within for new CEO
NIJMEGEN, Netherlands, April 25, 2024 /PRNewswire/ — ScreenPoint Medical, today announced a significant transition in its leadership as Mark Koeniguer, the current CEO, steps down from his position. Mark served as CEO since 2022 and was instrumental in ScreenPoint’s commercial growth and success over the past 2 years.
The company’s Board of Directors has appointed Pieter Kroese as the new Chief Executive Officer effective April 25, 2024. Pieter takes the role after serving as COO of ScreenPoint for over five years. During that time, he has managed the transition of the company from an early startup to a thriving enterprise with hundreds of customers using ScreenPoint’s flagship Transpara software to support millions of scans a year.
“I am thrilled to lead ScreenPoint into its next phase of growth and innovation,” said Mr. Kroese. “I am deeply committed to building upon the strong foundation we have and continuing to work closely with our talented team to drive continued success. We are already expanding screening capacity and capability through proven reader support – we look forward to increasing our ability to support providers and women moving forward.”
Sir Michael Brady, Chairman of the Board at ScreenPoint Medical and a co-founder of the company, expressed enthusiasm about Pieter’s appointment, stating, “Pieter’s remarkable leadership qualities, coupled with his depth of knowledge of our product and industry, make him the perfect choice to lead ScreenPoint into the future. His strategic mindset and commitment to excellence align perfectly with our company mission of early breast cancer detection. Pieter has been an integral part of our growth to date and will provide seamless leadership through this transition into our next chapter for our customers, partners, and team.”
Author of “No Longer Radical” and over a hundred peer-reviewed publications on breast imaging, Dr. Rachel Brem is a Transpara user and ScreenPoint Board Member. Dr. Brem welcomed Mr. Kroese with the following: “Pieter has been an integral part of the ScreenPoint team for years. I am confident that his leadership will continue to deliver product excellence: earlier detection with outstanding reading workflow and improved patient outcomes. We continue to see these results from clinical sites all over the world, including many here in the United States. No other Breast AI solution has demonstrated the same results as Transpara, and I am confident that the team will continue to push on these frontiers under Pieter’s leadership.”
The entire team at ScreenPoint extends its gratitude to Mark Koeniguer and wishes him every success in the future, while warmly welcoming Pieter Kroese into his new role as CEO.
About ScreenPoint Medical
ScreenPoint Medical translates cutting edge machine learning research into technology accessible by radiologists to improve screening workflow, decision confidence and breast cancer risk assessment. Transpara is trusted by radiologists globally because it has been developed by experts in machine learning and image analysis and updated with user feedback from world-renowned breast imagers.
See all the proof at: https://screenpoint-medical.com/evidence.
Photo: https://mma.prnewswire.com/media/2397831/Pieter_Kroese_CEO_ScreenPoint_Medical.jpgLogo: https://mma.prnewswire.com/media/1582198/ScreenPoint_Medical_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/screenpoint-medical-leadership-transition-pieter-kroese-confirmed-as-ceo-302127719.html
-
Uncategorized6 days agoGenerative AI gold rush drives IT spending — with payoff in question
-
Uncategorized6 days ago
Do underwriters trust artificial intelligence?
-
Uncategorized6 days ago
Hans Jonas on Responsibility in the Age of Artificial Intelligence
-
Uncategorized6 days ago
Meta AI Assistant Adds Website, Expands Beyond US
-
Artificial Intelligence6 days agoFree Your Hands, QIDI Vida Smart AR Glasses Lead the Way in New Sports Experience.
-
Uncategorized6 days ago
Can artificial intelligence reduce vehicle time to market?
-
Uncategorized6 days ago
The Ottawa Hospital doctors to try AI for patient notes
-
Artificial Intelligence5 days agoAurionpro Solutions acquires Arya.ai, to power next generation Enterprise AI platforms for Financial Institutions
